Cargando…

Identifying enriched drug fragments as possible candidates for metabolic engineering

BACKGROUND: Fragment-based approaches have now become an important component of the drug discovery process. At the same time, pharmaceutical chemists are more often turning to the natural world and its extremely large and diverse collection of natural compounds to discover new leads that can potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Sunandini, Karri, Kritika, Thapa, Ishwor, Bastola, Dhundy, Ghersi, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980782/
https://www.ncbi.nlm.nih.gov/pubmed/27510651
http://dx.doi.org/10.1186/s12920-016-0205-6
_version_ 1782447514705723392
author Sharma, Sunandini
Karri, Kritika
Thapa, Ishwor
Bastola, Dhundy
Ghersi, Dario
author_facet Sharma, Sunandini
Karri, Kritika
Thapa, Ishwor
Bastola, Dhundy
Ghersi, Dario
author_sort Sharma, Sunandini
collection PubMed
description BACKGROUND: Fragment-based approaches have now become an important component of the drug discovery process. At the same time, pharmaceutical chemists are more often turning to the natural world and its extremely large and diverse collection of natural compounds to discover new leads that can potentially be turned into drugs. In this study we introduce and discuss a computational pipeline to automatically extract statistically overrepresented chemical fragments in therapeutic classes, and search for similar fragments in a large database of natural products. By systematically identifying enriched fragments in therapeutic groups, we are able to extract and focus on few fragments that are likely to be active or structurally important. RESULTS: We show that several therapeutic classes (including antibacterial, antineoplastic, and drugs active on the cardiovascular system, among others) have enriched fragments that are also found in many natural compounds. Further, our method is able to detect fragments shared by a drug and a natural product even when the global similarity between the two molecules is generally low. CONCLUSIONS: A further development of this computational pipeline is to help predict putative therapeutic activities of natural compounds, and to help identify novel leads for drug discovery.
format Online
Article
Text
id pubmed-4980782
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49807822016-08-19 Identifying enriched drug fragments as possible candidates for metabolic engineering Sharma, Sunandini Karri, Kritika Thapa, Ishwor Bastola, Dhundy Ghersi, Dario BMC Med Genomics Research BACKGROUND: Fragment-based approaches have now become an important component of the drug discovery process. At the same time, pharmaceutical chemists are more often turning to the natural world and its extremely large and diverse collection of natural compounds to discover new leads that can potentially be turned into drugs. In this study we introduce and discuss a computational pipeline to automatically extract statistically overrepresented chemical fragments in therapeutic classes, and search for similar fragments in a large database of natural products. By systematically identifying enriched fragments in therapeutic groups, we are able to extract and focus on few fragments that are likely to be active or structurally important. RESULTS: We show that several therapeutic classes (including antibacterial, antineoplastic, and drugs active on the cardiovascular system, among others) have enriched fragments that are also found in many natural compounds. Further, our method is able to detect fragments shared by a drug and a natural product even when the global similarity between the two molecules is generally low. CONCLUSIONS: A further development of this computational pipeline is to help predict putative therapeutic activities of natural compounds, and to help identify novel leads for drug discovery. BioMed Central 2016-08-10 /pmc/articles/PMC4980782/ /pubmed/27510651 http://dx.doi.org/10.1186/s12920-016-0205-6 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Sharma, Sunandini
Karri, Kritika
Thapa, Ishwor
Bastola, Dhundy
Ghersi, Dario
Identifying enriched drug fragments as possible candidates for metabolic engineering
title Identifying enriched drug fragments as possible candidates for metabolic engineering
title_full Identifying enriched drug fragments as possible candidates for metabolic engineering
title_fullStr Identifying enriched drug fragments as possible candidates for metabolic engineering
title_full_unstemmed Identifying enriched drug fragments as possible candidates for metabolic engineering
title_short Identifying enriched drug fragments as possible candidates for metabolic engineering
title_sort identifying enriched drug fragments as possible candidates for metabolic engineering
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980782/
https://www.ncbi.nlm.nih.gov/pubmed/27510651
http://dx.doi.org/10.1186/s12920-016-0205-6
work_keys_str_mv AT sharmasunandini identifyingenricheddrugfragmentsaspossiblecandidatesformetabolicengineering
AT karrikritika identifyingenricheddrugfragmentsaspossiblecandidatesformetabolicengineering
AT thapaishwor identifyingenricheddrugfragmentsaspossiblecandidatesformetabolicengineering
AT bastoladhundy identifyingenricheddrugfragmentsaspossiblecandidatesformetabolicengineering
AT ghersidario identifyingenricheddrugfragmentsaspossiblecandidatesformetabolicengineering